CL2011002643A1 - Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c. - Google Patents

Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.

Info

Publication number
CL2011002643A1
CL2011002643A1 CL2011002643A CL2011002643A CL2011002643A1 CL 2011002643 A1 CL2011002643 A1 CL 2011002643A1 CL 2011002643 A CL2011002643 A CL 2011002643A CL 2011002643 A CL2011002643 A CL 2011002643A CL 2011002643 A1 CL2011002643 A1 CL 2011002643A1
Authority
CL
Chile
Prior art keywords
ritonavir
hepatitis
virus
kit
pharmaceutical composition
Prior art date
Application number
CL2011002643A
Other languages
English (en)
Inventor
Jonathan Q Tran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2011002643A1 publication Critical patent/CL2011002643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procedimiento para incrementar la biodisponibilidad de un inhibidor de proteasa ns3/4a del virus de la hepatitis C que comprende la coadministración de un compuesto r7227 y ritonavir; composición farmacéutica que los comprende y kit.
CL2011002643A 2009-04-25 2011-10-24 Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c. CL2011002643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25

Publications (1)

Publication Number Publication Date
CL2011002643A1 true CL2011002643A1 (es) 2012-05-25

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002643A CL2011002643A1 (es) 2009-04-25 2011-10-24 Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.

Country Status (36)

Country Link
US (4) US20100272682A1 (es)
EP (1) EP2421527B1 (es)
JP (1) JP5523552B2 (es)
KR (1) KR101471238B1 (es)
CN (2) CN102413827A (es)
AR (1) AR076388A1 (es)
AU (1) AU2010240893B2 (es)
BR (1) BRPI1015147B1 (es)
CA (1) CA2758644C (es)
CL (1) CL2011002643A1 (es)
CO (1) CO6440593A2 (es)
CR (1) CR20110551A (es)
DK (1) DK2421527T3 (es)
EC (1) ECSP11011420A (es)
ES (1) ES2683736T3 (es)
HK (1) HK1215858A1 (es)
HR (1) HRP20181306T1 (es)
HU (1) HUE040182T2 (es)
IL (1) IL215620A (es)
LT (1) LT2421527T (es)
MA (1) MA33212B1 (es)
MX (2) MX2011011105A (es)
MY (1) MY169734A (es)
NZ (1) NZ595917A (es)
PE (1) PE20120638A1 (es)
PL (1) PL2421527T3 (es)
PT (1) PT2421527T (es)
RS (1) RS57501B1 (es)
RU (1) RU2591830C2 (es)
SG (1) SG175328A1 (es)
SI (1) SI2421527T1 (es)
TR (1) TR201809600T4 (es)
TW (1) TWI468160B (es)
UA (1) UA103801C2 (es)
WO (1) WO2010122087A1 (es)
ZA (1) ZA201107421B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2863002A1 (en) 2012-01-11 2013-07-18 Abbvie Inc. Processes for making hcv protease inhibitors
WO2014004674A2 (en) * 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102686313B1 (ko) * 2014-05-01 2024-07-17 아이거 바이오파마슈티컬스 인코포레이티드 델타 간염 바이러스 감염의 치료
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10835496B2 (en) 2015-04-21 2020-11-17 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69305093T2 (de) 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
WO2002008187A1 (en) * 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US20040152625A1 (en) 2002-12-16 2004-08-05 Boehringer Ingelheim International Gmbh Method for improving the pharmacokinetics of an NNRTI
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
DK2421527T3 (en) 2018-08-13
ES2683736T3 (es) 2018-09-27
MA33212B1 (fr) 2012-04-02
TW201041582A (en) 2010-12-01
MY169734A (en) 2019-05-14
EP2421527B1 (en) 2018-06-13
WO2010122087A1 (en) 2010-10-28
TR201809600T4 (tr) 2018-07-23
RU2591830C2 (ru) 2016-07-20
BRPI1015147A2 (pt) 2018-01-30
AU2010240893A1 (en) 2011-11-03
PT2421527T (pt) 2018-08-02
RU2011142651A (ru) 2013-05-27
TWI468160B (zh) 2015-01-11
SG175328A1 (en) 2011-11-28
UA103801C2 (ru) 2013-11-25
SI2421527T1 (sl) 2018-09-28
US10918626B2 (en) 2021-02-16
LT2421527T (lt) 2018-09-10
US20180318267A1 (en) 2018-11-08
CA2758644C (en) 2018-01-09
AU2010240893B2 (en) 2015-02-05
HK1215858A1 (zh) 2016-09-23
ECSP11011420A (es) 2011-11-30
CN105233249A (zh) 2016-01-13
HRP20181306T1 (hr) 2018-10-19
AR076388A1 (es) 2011-06-08
RS57501B1 (sr) 2018-10-31
ZA201107421B (en) 2022-11-30
CA2758644A1 (en) 2010-10-28
CN102413827A (zh) 2012-04-11
US20200230112A1 (en) 2020-07-23
IL215620A0 (en) 2012-01-31
EP2421527A1 (en) 2012-02-29
MX351185B (es) 2017-10-04
BRPI1015147B1 (pt) 2022-03-08
CO6440593A2 (es) 2012-05-15
PL2421527T3 (pl) 2018-10-31
JP2012524753A (ja) 2012-10-18
KR20120014170A (ko) 2012-02-16
KR101471238B1 (ko) 2014-12-12
JP5523552B2 (ja) 2014-06-18
MX2011011105A (es) 2011-11-18
US20170119739A1 (en) 2017-05-04
US20100272682A1 (en) 2010-10-28
NZ595917A (en) 2014-02-28
PE20120638A1 (es) 2012-05-26
HUE040182T2 (hu) 2019-02-28
IL215620A (en) 2015-10-29
CR20110551A (es) 2011-12-13

Similar Documents

Publication Publication Date Title
CO6501153A2 (es) Inhibidores macrociclicos de serina proteasa
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
ECSP11011065A (es) Composición farmacéutica de un potente inhibidor de hcv para su administración oral
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
CL2011002377A1 (es) Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c.
AR076388A1 (es) Procedimientos para mejorar la farmocinetica
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
CR20120418A (es) Inhibidores de virus flaviviridae
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
ECSP045223A (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
BR112014000563A2 (pt) composto, composição farmacêutica, e, uso do composto
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
MX2013000642A (es) Composiciones farmaceuticas.
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
ECSP13012791A (es) Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
IN2012DN01855A (es)
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias